Luteinizing hormone Completed Phase 2 Trials for Prostate Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00283803Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer